Paliperidon Teva (Paliperidone Palmitate)

Paliperidone palmitate works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors in the brain, which diminishes dopaminergic and serotonergic neurotransmission associated with psychotic symptoms. Additional antagonism of α1‑adrenergic and histamine H1 receptors contributes to its overall effect, while the depot formulation maintains steady plasma levels for weeks, supporting continuous symptom control.

The dosing regimen for paliperidone palmitate is individualized by the prescribing clinician based on the patient’s clinical status, prior response, and tolerability. The prescriber determines the injection strength, interval (typically every 4 weeks after the initial loading doses), and any necessary adjustments, following the product’s approved labeling and local guidelines.

Safety data for paliperidone palmitate in pregnancy and lactation are limited, and the drug is generally prescribed only when the potential benefits to the mother outweigh any possible risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and alternative treatment options with their healthcare provider.

To request Paliperidon Teva, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and assistance with import documentation.

Compared with oral atypical antipsychotics, paliperidone palmitate offers a long‑acting injectable option that improves adherence by reducing the need for daily dosing. Relative to other depot antipsychotics, it shares a similar receptor profile but differs in dosing intervals and formulation. Clinicians consider efficacy, side‑effect profile, patient preference, and previous treatment response when selecting between paliperidone palmitate and alternative agents.

Paliperidon Teva should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. The product must not be frozen or exposed to extreme temperatures. Proper storage helps maintain the stability of the injectable suspension and ensures the medication remains effective until the expiration date.

Paliperidon Teva is given as an intramuscular injection, typically into the deltoid or gluteal muscle, by a qualified healthcare professional. The initial regimen usually involves one or two loading doses to rapidly achieve therapeutic plasma concentrations, followed by maintenance injections at regular intervals (often every four weeks). Injection technique and site rotation are important to minimize local reactions.

The most serious adverse reactions to consider include neuroleptic malignant syndrome, a potentially fatal condition characterized by fever, muscle rigidity, and autonomic instability; tardive dyskinesia, which may cause persistent involuntary movements; and severe allergic reactions such as anaphylaxis. Patients should be monitored closely for early signs of these events, and treatment should be discontinued if they occur.

Paliperidon Teva is contraindicated in individuals with known hypersensitivity to paliperidone, paliperidone palmitate, or any excipients in the formulation. It should also be avoided in patients with a history of neuroleptic malignant syndrome or severe uncontrolled cardiovascular conditions. Caution is advised for those with significant hepatic or renal impairment, and the medication should be used only under close medical supervision in such cases.